Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 17/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7613625 | 0.94 | CHRM4 (0.64) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6914990 | 0.85 | CHRM4 (0.81) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL7611918 | 0.85 | CHRM4 (0.81) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6915131 | 0.84 | CHRM4 (0.83) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6914306 | 0.84 | CHRM1 (0.80) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7900811 | 0.84 | CHRM4 (0.97) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6915591 | 0.83 | CHRM1 (0.82) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6912866 | 0.83 | CHRM4 (0.76) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL4035543 | 0.82 | CHRM1 (1.00) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6915821 | 0.82 | CHRM1 (0.73) | CHRM4CHRM1CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | claimed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | claimed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| EP-1316203-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002003684-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-0709094-B1 | Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety | LILLY CO ELI (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5708014-A | SUBSTITUTED TETRAHYDROPYRIDINYL-1,2,5-OXADIAZOLES OR THIADIAZOLES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0709094-A2 | Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM4 2/4885CHRM1 8/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.